Leitlinie
Fine-Tuning Cancer Risk and Response: Practical Implications of the 2025 ATA Differentiated Thyroid Cancer Guidelines
Clinical Thyroidology® · 01.11.2026 · 38 (11) · 389-392
DOI: 10.1177/23299711261506067 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical Thyroidology®, online erschienen am 16.11.2026. Verfasst von Maya Taleb und 1 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Taleb, M., & Genere, N. (2026). Fine-Tuning Cancer Risk and Response: Practical Implications of the 2025 ATA Differentiated Thyroid Cancer Guidelines. Clinical Thyroidology®, 38(11), 389-392. https://doi.org/10.1177/23299711261506067
Vancouver
Taleb M, Genere N. Fine-Tuning Cancer Risk and Response: Practical Implications of the 2025 ATA Differentiated Thyroid Cancer Guidelines. Clinical Thyroidology®. 2026;38(11):389-392. doi:10.1177/23299711261506067
BibTeX
@article{Taleb2026,
author = {Taleb, Maya and Genere, Natalia},
title = {Fine-Tuning Cancer Risk and Response: Practical Implications of the 2025 ATA Differentiated Thyroid Cancer Guidelines},
journal = {Clinical Thyroidology®},
year = {2026},
volume = {38},
number = {11},
pages = {389--392},
doi = {10.1177/23299711261506067}
}
EUVIMED